anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary science. The method involves a subcutaneous injection of reconvascelent blood serum containing rota- and coronavirus antihemagglutinins. It is combined with an intake of 70% alcoholate of a grinded herbal mixture containing equal proportions of purple Echinacea (Echinazea purpurea) herb and blossom clusters, Syrian rue (Peganum harmala) herb, tillet (Tilia cordata) blossom and common licorice (Glycyrrhiza glabra) roots. The alcoholate is prepared in the raw material to extractant relation 1:10, kept at temperature 15-20C for 7 days. It is presented as 7-8% aqueous solution to be introduced in dosage 2.0-2.5 ml/kg of live weight every 12 hours to clinical recovery. ^ EFFECT: method provides higher resistance and fast micro- and macroelements rebalancing in an animal's organism. ^ 5 tbl, 3 ex
The present invention relates to a capsule refined by pure traditional Chinese medicine for treating the nonliquefaction of semen and a preparation method thereof. The capsule is prepared by the further sieving through the combination of modern pharmacology research on the basis of clinical practices for many years. The capsule is composed of curcuma root, hemlock parsley, common prism tuber, leech, suberect spatholobus, Chiese eaglewood wood, combined spicebush root, angelica and endothelium corneae gigeriae galli. The capsule has the functions of platelet aggregation inhibition, platelet coagulation prevention, inflammation resistance, tranquilization, pain alleviation, improvement of the immunological function, etc. The capsule enables active ingredients to be sufficiently absorbed and utilized to perform functions to a maximum extent, and has the advantages of rapid effect, small volume, simple preparation, medicinal material saving, stable quality, portability and convenient administration. In addition, a patient can carry the capsule at any time for longtime administration. Thus, the capsule has dual treating effects on integration and parts. Pharmacodynamics experiments prove that the capsule has obvious effects of treating the nonliquefaction of semen, prostatitis and systemic diseases caused by qi stagnation and blood stasis, and strengthening the immunological function of bodies through clinical observation and the experiments of coagulation prevention, bacterium inhibition, tranquilization and pain alleviation in vitro.
PURPOSE: An image display method and an ultrasonic diagnosing apparatus are provided to redisplay an image displayed when releasing a freeze after releasing the freeze. CONSTITUTION: A transmitter and receiver unit(2) scans an object using an ultrasonic wave and obtains a sound line data. A signal processing unit(3) generates an image data set based on the sound line data to one image. A cine memory(4) stores a plurality of image data sets, overwrites the stored longest image as a recent image, and stores a plurality of recent image data sets. A digital scan converter(5) recalls one image data set among a plurality of image data sets from the cine memory(4) for generating a display image. A display unit(6) displays the display image. A controller(7) performs a control such as a selection of the image data set recalled from the cine memory(4) to a DSC.
In the department of Boyacá, Colombia, agriculture stands as one of the primary economic activities. However, the escalating utilization of pesticides within this sector has sparked concern regarding its potential correlation with elevated risks of genotoxicity, chromosomal alterations, and carcinogenesis. Furthermore, pesticides have been associated with a broad spectrum of genetic polymorphisms that impact pivotal genes involved in pesticide metabolism and DNA repair, among other processes. Nonetheless, our understanding of the genotoxic effects of pesticides on the chromosomes (as biomarkers of effect) in exposed farmers and the impact of genetic polymorphisms (as susceptibility biomarkers) on the increased risk of chromosomal damage is still limited. The aim of our study was to evaluate chromosomal alterations, chromosomal instability, and clonal heterogeneity, as well as the presence of polymorphic variants in the GSTP1 and XRCC1 genes, in peripheral blood samples of farmers occupationally exposed to pesticides in Aquitania, Colombia, and in an unexposed control group. Our results showed statistically significant differences in the frequency of numerical chromosomal alterations, chromosomal instability, and clonal heterogeneity levels between the exposed and unexposed groups. In addition, we also found a higher frequency of chromosomal instability and clonal heterogeneity in exposed individuals carrying the heterozygous GSTP1 AG and XRCC1 (exon 10) GA genotypes. The evaluation of chromosomal alterations and chromosomal instability resulting from pesticide exposure, combined with the identification of polymorphic variants in the GSTP1 and XRCC1 genes, and further research involving a larger group of individuals exposed to pesticides could enable the identification of effect and susceptibility biomarkers. Such markers could prove valuable for monitoring individuals occupationally exposed to pesticides.
PROBLEM TO BE SOLVED: To obtain a new hollow spherical material which is simply produced on a large scale by culturing a microorganism comprising a specific cell wall fiber of chitosan-containing Zygomycetes, having biodegradability, several metal ions adsorbing character and medicine attaching function. SOLUTION: The outer shell of this new hollow spheres are composed of porous complex of cell wall fibers of germ belonging to genus Rhizopus containing more than 20% of chitosan and the diameters of the spheres are 0.2-2mm. In the process to obtain this objective material, Rhizopus germ (example; Rhizopus acetoirus HUT1219 strain) is cultured in a liquid culture containing 0.5-3.2% of alcohol such as methanol, ethanol, propanol, etc., allowing them to form granular cell cluster. Sodium carbonate or sodium hydroxide solution of 2-10wt.%/vol is added to this cell cluster in amount of 50-100 times of the weight of the dried cell cluster, heat treated at 90-130 deg.C followed by washing with water and drying. The heat treatment is preferably carried out in an autoclave. The thickness of the outer shell of the objective material is preferably 40-70μm.
An extended wear electrocardiography and physiological sensor monitor is provided. An electrode patch includes an integrated flexible circuit having a single piece of material that includes a longitudinal midsection between upper and lower ends and a mirror image shape of the upper end extending from at least a portion of one side of the upper end that runs substantially parallel to the midsection and folds over the upper end. A receptacle is adhered on an outward surface of the mirror image when the integrated circuit is folded over the upper end. One electrode is positioned on a contact surface of the integrated circuit on the upper end and another electrode is positioned on the contact surface on the lower end. A battery is directly adhered to the outward surface of the mirror image and positioned under the receptacle. A monitor is configured to be removably secured in the receptacle.
A method for obtaining a cell mixture which contains rich hepatic progenitor cells is established. A method for generating a plurality of kinds of cell mixture suspension, and a method for screening cells which have classic MHCI antigen negative performance and ICAM-1 antigen positive performance are supplied. Weak expression or feebleness expression of non-classic MHCI antigen can be used for further enriching hepatic progenitor cells. In addition, because progenitor cells have a certain level of lateral scattering, the progenitor cells are selected, which is a testing method for granularity or cytoplasmic droplets. The progenitor cells are more than nonparenchymal cells, such as hematopoietic cells, and the progenitor cells are less than mature parenchyma cells, such as liver cells. Furthermore, offspring of divided progenitor cells can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitor cells which are divided like this can grow in an asexuality propagation mode, namely that a whole group of offspring can come from one cell. Clone of progenitor cells has the growth characteristic of aggregation in stacks or groups during cultivation. The methods for dividing hepatic progenitor cells can be applied to any vertebrate including a human being. A prospective hepatic progenitor cell group can be used for cell therapy, biologic artificial livers, gene therapy, development of vaccine, and various projects and research of toxicology, pharmacology and pharmacy.
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic overcoming defects of usual cosmetics peculiarly appearing under a light source for photographing such as loss of brightness or a trace of fixing of makeup. SOLUTION: This solid makeup cosmetic for bodies contains 30-40 wt.% of a powder. In the solid makeup cosmetic, the powder is only one or more kinds selected from titanium dioxide, yellow iron oxide, red iron oxide, prussian blue, ultramarine, chromium oxide, chromium hydroxide, Red No. 201, Red No. 202, Red No. 226, Yellow No. 4 lake, Yellow No. 401, Blue No. 404 and silica-titanium sericite-silica multilayered coating powder which may be doped with other metal atoms. The cosmetic further contains 10-15 wt.% of dimethicone and 5-10 wt.% of a polyethylene having >=20 and <=30 average degree of polymerization.
An assay comprises contacting cells containing a conformationally altered protein with test compound and determining if the altered protein is cleared. The cells may be scrapie-infected neuroblastoma cells. Another assay comprises contacting organ or tissue homogenate (at pH 5.0 or less) with test compound to determine if altered protein in the homogenate is cleared. The homogenate may be brain homogenate from a transgenic mouse infected with human prions. Compounds which are found to clear the altered protein are useful in preventing, arresting and/or reversing (i.e. treating) a disease associated with the conformationally altered protein.
The t(X,17) chromosomal translocation, generating the ASPSCR1::TFE3 fusion oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some Xp11-rearranged renal cell carcinomas (RCCs), frustrating efforts to identify therapeutic targets for these rare cancers. Here, proteomic analysis identifies VCP/p97, an AAA+ ATPase with known segregase function, as strongly enriched in co-immunoprecipitated nuclear complexes with ASPSCR1::TFE3. We demonstrate that VCP is a likely obligate co-factor of ASPSCR1::TFE3, one of the only such fusion oncoprotein co-factors identified in cancer biology. Specifically, VCP co-distributes with ASPSCR1::TFE3 across chromatin in association with enhancers genome-wide. VCP presence, its hexameric assembly, and its enzymatic function orchestrate the oncogenic transcriptional signature of ASPSCR1::TFE3, by facilitating assembly of higher-order chromatin conformation structures demonstrated by HiChIP. Finally, ASPSCR1::TFE3 and VCP demonstrate co-dependence for cancer cell proliferation and tumorigenesis in vitro and in ASPS and RCC mouse models, underscoring VCP's potential as a novel therapeutic target.
The trial will evaluate the efficacy and safety of CF102 as compared to placebo. Subjects will be randomly assigned in a 2:1 ratio to treatment with oral doses of either CF102 25 mg or matching placebo administered twice daily (BID) for consecutive, 28-day cycles. Subjects will be evaluated regularly for safety. Tumor imaging will be performed every 8 weeks. Treatment will continue until the subject experiences unacceptable drug-related intolerability. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug, and every attempt will be made to obtain survival data on all randomized subjects. Subjects who discontinue will be followed indefinitely for survival status. The trial will continue until 75 deaths have been recorded.
Fluvastatin capsules are contraindicated in women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Fluvastatin may cause fetal harm when administered to pregnant women. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. 

Fluvastatin capsules should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, fluvastatin capsules should be discontinued and the patient should be apprised of the potential hazard to the fetus [see Use In Specific Populations (8.1)].
Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
PURPOSE: The purpose of this study was to investigate the protective effect of CD38 deletion on retinal ganglion cells (RGCs) in a mouse retinal ischemia/reperfusion (I/R) model and an optic nerve crush (ONC) model, and to elucidate the underlying molecular mechanisms.
METHODS: Retinal I/R and ONC models were constructed in mice. PCR was used to identify the deletion of CD38 gene in mice, hematoxylin and eosin (H&E) staining was used to evaluate the changes in retinal morphology, and electroretinogram (ERG) was used to evaluate the changes in retinal function. The survival of RGCs and activation of retinal macroglia were evaluated by immunofluorescence staining. The expression of Sirt1, CD38, Ac-p65, Ac-p53, TNF-α, IL-1β, and Caspase3 proteins in the retina was further evaluated by protein imprinting.
RESULTS: In retinal I/R and ONC models, CD38 deficiency reduced the loss of RGCs and activation of macroglia and protected the retinal function. CD38 deficiency increased the concentration of NAD+, reduced the degree of acetylation of NF-κB p65 and p53, and reduced expression of the downstream inflammatory cytokines TNFα, IL-1β, and apoptotic protein Caspase3 in the retina in the ONC model. Intraperitoneal injection of the Sirt1 inhibitor EX-527 partially counteracted the effects of CD38 deficiency, suggesting that CD38 deficiency acts at least in part through the NAD+/Sirt1 pathway.
CONCLUSIONS: CD38 plays an important role in the pathogenesis of retinal I/R and ONC injury. CD38 deletion protects RGCs by attenuating inflammatory responses and apoptosis through the NAD+/Sirt1 pathway.
Treatment strategies that are efficient against established Alzheimer's disease (AD) are needed. BRICHOS is a molecular chaperone domain that prevents amyloid fibril formation and associated cellular toxicity. In this study, we treated an AD mouse model seven months after pathology onset, using intravenous administration of recombinant human (rh) Bri2 BRICHOS R221E. Two injections of rh Bri2 BRICHOS R221E per week for three months in AD mice reduced amyloid β (Aβ) burden, and mitigated astro- and microgliosis, as determined by glial fibrillary acidic protein (GFAP) and ionized calcium-binding adaptor molecule 1 (Iba1) immunohistochemistry. Sequencing of RNA from cortical microglia cells showed that BRICHOS treatment normalized the expression of identified plaque-induced genes in mice and humans, including clusterin and GFAP. Rh Bri2 BRICHOS R221E passed the blood-brain barrier (BBB) in age-matched wild-type mice as efficiently as in the AD mice, but then had no effect on measures of AD-like pathology, and mainly affected the expression of genes that affect cellular shape and movement. These results indicate a potential of rh Bri2 BRICHOS against advanced AD and underscore the ability of BRICHOS to target amyloid-induced pathology.
ETHNOPHARMACOLOGICAL RELEVANCE: Panax ginseng C. A. Mey., one of the most used herbs in the world, shows effective treatment in reproductive injury. Recent studies have proven that the processed product, red ginseng, which is more active than ginseng itself. Therefore, it is speculated that its main functional component, rare ginsenosides (heat-transformed saponin, HTS), may be effective in treating premature ovarian failure (POF), but its efficacy has not yet been experimentally confirmed.
AIM OF THE STUDY: To evaluate whether HTS could attenuate cyclophosphamide-induced inflammation and oxidative damage in POF model rats and the human granulosa-like KGN cell line and protect granulosa cell proliferation.
MATERIAL AND METHODS: HTS were isolated from ginsenosides and high performance liquid chromatography (HPLC) analysis was used to analyze the HTS components. Cyclophosphamide (CP) was used to establish a POF rat model and KGN cell injury model. Reactive oxygen species (ROS) and antioxidant enzyme production was determined using specific assays, while inflammatory cytokine secretion was measured by enzyme-linked immunosorbent assay (ELISA). The proliferative function of granulosa cells was assessed using high-content screening and immunohistochemistry to determine the Ki67 protein level. Protein expression in ovarian tissues and KGN cells was analyzed by Western blotting, quantitative real-time PCR (qRT-PCR) was used to determine the transcriptional changes in ovarian tissues and KGN cells.
RESULTS: In CP-treated POF model rats, HTS significantly decreased malondialdehyde (MDA), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels, increased glutathione oxidase (GSH) levels, and upregulated Ki67 expression in ovarian granulosa cells. In addition, HTS significantly increased cell survival and Ki67 expression levels in CP-treated cells, and superoxide dismutase (SOD) levels were significantly increased. HTS significantly downregulated IL-6, TNF-α, and interleukin-1β (IL-1β) mRNA expression and significantly inhibited nuclear factor kappa-B p65 (NF-κB p65) and p38 mitogen activated protein kinase (p38 MAPK) phosphorylation in POF model rats and KGN cells. Moreover, NF-κB p65 and p38 MAPK levels were significantly increased in ovarian granulosa cells. p65 and p38 protein and gene expression was significantly downregulated.
CONCLUSION: HTS ameliorated CP-induced POF and human granulosa cell injury, possibly by inhibiting inflammation and oxidative damage mediated by the p38 MAPK/NF-κB p65 signaling pathway.
Participants with HER2-low expressing unresectable and/or metastatic breast cancer who will be treated with trastuzumab deruxtecan and part of the enrolled participants will receive conventional chemotherapy. The participants on conventional chemotherapy will be analyzed exploratory only.
Participants in the waitlist control group will wait for 4 weeks without the training and then complete the post-intervention assessment. The waitlist control participants will start training (equivalent to that of the treatment group) immediately after completing the post-intervention assessment.
This invention is directed to a novel method for direct in vivo electrotransfection of a plurality of cells of a target tissue. In the method, the target is perfused with a transfection solution. An exterior electrode is positioned so as to surround at least a portion of the target tissue. One or more interior electrodes are placed within the target tissue. The perfusion and the application of the interior and exterior electrodes may be performed in any particular order. After the perfusion and the positioning of the electrodes, both interior and exterior, an electric waveform is applied through the exterior electrode and the interior electrode to transfect the cells in the target tissue.
The use of benzodiazepines, including NAYZILAM, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)]. 

Before prescribing NAYZILAM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. Use of NAYZILAM, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of NAYZILAM along with monitoring for signs and symptoms of abuse, misuse, and addiction. Do not exceed the recommended dosing frequency; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
Viral preparation and corresponding use. The present invention relates to the use of viral preparations as a prophylactic treatment (vaccination) of protected crops: cucumber (cucumis sativus), zucchini (cucurbita pepo), pepper (capsicum annuum), eggplant (solanum melongena) and tomato (solanum lycopersicum) against a single-stranded rna virus belonging to the genus potexvirus, tobamovirus, potyvirus or tospovirus. It refers to the particle size and the particle size distribution in said viral preparation. An effective viral preparation has a bimodal distribution comprising two main fractions, the first size fraction having a particle size of 1 to 10 μm, and the second presenting a particle size of 50 to 500 μm. The first fraction is relevant for infectivity and the second is relevant for the stability of the viral preparation. Both fractions are relevant for effective vaccination under changing conditions. (Machine-translation by Google Translate, not legally binding)
Participants in this arm will undergo a 30-minute session of chair sitting in a non-swivel chair. Activities during this session include engaging in typical desk activities to simulate a natural office environment.
FIELD: medicine, clinical oncology. SUBSTANCE: invention relates to preparations used for treatment of patients with malignant neoplasms by photodynamic therapy method. Preparation for photodynamic therapy carrying out has sulfinated aluminium phthalocyanine that exhibits enhanced accumulation in tumor with respect to normal tissues. Preparation has additionally transport proteins (for example, human albumin or the mixture of blood serum albumins and globulins or other transport proteins) at weight ratio protein : phthalocyanine = 8:1, not less. EFFECT: increased accumulation of preparation in tumor, enhanced effectiveness of photodynamic therapy. 2 cl